Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Headache Wellness Center

Neither a doctor nor a teaching hospital

Research payments

$1,020,529

116 payments

Through program year 2025, Headache Wellness Center is reported as receiving $1,020,529 in research payments, across 116 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,413 6
2024 Research $19,463 5
2023 Research $7,864 3
2022 Research $99,683 14
2021 Research $557,862 42
2020 Research $207,505 24
2019 Research $123,740 22

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biohaven Pharmaceuticals, Inc. $421,188 20 payments
  2. Allergan Inc. $391,193 47 payments
  3. Amgen Inc. $84,199 15 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $58,531 5 payments
  5. H. Lundbeck A S $21,130 5 payments
  6. AbbVie, Inc. $19,266 14 payments
  7. Teva Pharmaceuticals USA, Inc. $14,597 8 payments
  8. Currax Pharmaceuticals LLC $6,825 1 payment
  9. Amneal Pharmaceuticals LLC $3,600 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $242,915 7 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $167,301 23 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $139,774 13 payments
  4. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $139,311 15 payments
  5. A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $87,747 1 payment
  6. A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Chronic Or Episodic Migraine $81,370 9 payments
  7. Work Productivity Study $55,334 6 payments
  8. Phase 2 Episodic Migraine Prophylaxis EMP $26,715 5 payments
  9. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments $14,597 8 payments
  10. Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Delayed-start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache $12,846 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record